References
- Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, . Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: A systematic overview. JAMA. 2004; 292:89–96.
- Murphy SA, Gibson CM, Morrow DA, . Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007;28:2077–86. Epub 2007 Jun 28. Review.
- Bertrand ME. Task force on the management of acute coronary syndromes of the european society of cardiology. Management of acute coronary syndromes in patients presenting without persistent ST segment elevation. Eur Heart J. 2002;23:1809–40.
- Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, . enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593–601.
- Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, . A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med. 1997;337:447–52.
- Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, . Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. The antithrombotic combination using tirofiban and enoxaparin. Am Heart J. 2002;144:470–7.
- Heer T, Juenger C, Gitt AK, Bauer T, Towae F, Zahn R . Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice. J Thromb Thrombolysis 2009;28:325–32. Epub 2008 Dec 20.
- Yan AT, Yan RT, Huynh T, DeYoung P, Weeks A, Fitchett DH. Bleeding and outcome in acute coronary syndrome: Insights from continuous electrocardiogram monitoring in the integrilin and enoxaparin randomized assessment of acute coronary syndrome treatment (INTERACT) trial. Am Heart J. 2008;156:769–75. Epub 2008 Jul 21.
- Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, . enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45–54.
- Macie C, Forbes L, Foster GA, Douketis JD. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 2004;125:1616–21.
- Lopes RD, Alexander KP, Manoukian SV, Bertrand ME, Feit F, White HD. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (acute catheterization and urgent intervention triage strategy) trial. J Am Coll Cardiol. 2009;53:1021–30. Erratum: J Am Coll Cardiol. 2009;53:1473.
- Ozpolat B, Yazkan R, Aksoy M, Dogan S. Spontaneous pectoral hematoma secondary to enoxaparin for the treatment of deep venous thrombosis in an elderly man. Anadolu Kardiyol Derg. 2008;8:E40.